Navigation Links
Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
Date:11/7/2007

SAN FRANCISCO, Nov. 7 /PRNewswire/ -- Epiphany Biosciences announced today that the first patient was enrolled in a Phase 2b clinical trial with valomaciclovir (EPB-348) for the treatment of herpes zoster, also known as shingles. Valomaciclovir is a highly potent anti-viral with enhanced delivery and bioavailability.

"The initiation of this dose-finding study is an important milestone in our development of valomaciclovir," said Fred Volinsky, MD, Chief Executive Officer. "Shingles, especially in the elderly population, can pose a serious threat to quality of life. Despite the approval of the adult zoster vaccine, we believe that the potential market for effective zoster medications will double in size based on the published vaccine efficacy rates and the aging of the baby boomers."

"There are roughly one million cases of herpes zoster in the United States annually and current therapy requires multiple dosing, anywhere from three to five times a day. These dosing schedules can be problematic for patient populations who are already taking multiple medications for other co-morbid conditions," stated Brian Murphy, MD, Chief Medical Officer. "This clinical trial is designed to examine the safety and efficacy of once-daily valomaciclovir against an active comparator, three times daily valacyclovir, and is adequately powered to assess a number of pivotal outcomes."

"Advancing a therapy that is conducive to better compliance is sorely needed in this therapeutic space," noted Dr. Stephen Tyring, Professor of Medicine at the University of Texas Health Science Center in Houston and principal investigator for the study. "In light of the improved pharmacodynamic profile offered by this drug, it is important to study it in larger, diverse populations that can be affected by herpes zoster."

The number of elderly patients at-risk for this disease is expected to increase dramatically over the next decade as the world population ages. "While we are work
'/>"/>

SOURCE Epiphany Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... and NYSE: SNY ) today announced that ... people with hypercholesterolemia met their primary efficacy endpoint of ... cholesterol (LDL-C) at 24 weeks compared to placebo or ... PCSK9 (proprotein convertase subtilisin/kexin type 9). In ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Eisai ... announced today that an article based on post-hoc analyses from ... Weight Loss While on Lorcaserin, Diet, and Exercise as a ... the online issue of Obesity , the official peer ... analyses was to identify whether there is an early treatment ...
(Date:7/30/2014)... 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), ... its expertise in opioid antagonists, announced today that ... prominent international research and development foundation. ... research-based initiatives, including those addressing health issues. Lightlake ... delivery of naloxone that could widely expand its ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... April 29 Wellcore Corporation, a Silicon Valley-based ... safety, begins shipping its highly anticipated Wellcore system today. ... live more active, independent lives, the Wellcore system offers ... will work outside of the home, unlike other fall ...
... on pharma industry , , , ... two whistleblower lawsuits that is being settled as part of Ortho-McNeil-Janssen Pharmaceuticals Inc.,s and Ortho-McNeil Pharmaceutical LLC,s ... northern Virginia . , , , ... , , ...
Cached Medicine Technology:The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available 2The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available 3Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 2Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 3Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 4
(Date:7/30/2014)... news of an Ohio teen who died of a ... the normally well-tolerated and mass-consumed substance. To help prevent ... much caffeine, scientists are reporting progress toward a rapid, ... stimulant in most beverages and even breast milk. Their ... Food Chemistry . , Mani Subramanian and colleagues note ...
(Date:7/30/2014)... Los Angeles, CA (PRWEB) July 30, 2014 ... Ghasri, now offers comprehensive cosmetic dental treatments that can ... office, Sunset Plaza Dental. Healthy teeth and gums form ... affect a person’s smile. While minor chips, misshapen teeth ... can all detract from a smile’s appearance. The right ...
(Date:7/30/2014)... 2014 All the children at Father’s ... rejection, abuse and exploitation tend to mar their respective ... and dejection. Quality youth development has underpinnings in a ... boosts confidence and in the foreseeable future, would assist ... light that the mere presence of Foundation members in ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- ,Middle-aged adults ... twice as likely as others to develop severe memory ... The British researchers said their findings could help ... might benefit from help for problem drinking. "We ... and levels of current alcohol consumption -- that understanding ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 We know pregnancy ... to peanut butter and ice cream—but the latest episode of ... MDs , just posted online, has a recipe that is ... a James Beard Award-winning chef serves up an easy recipe ... is the executive chef at Rasika, which was named one ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 3Health News:The Edusei Foundation Donates Food and Assorted Items to the Fathers’ Home Care Ministries in Takoradi, Ghana 2Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2Health News:What to Eat When You’re Expecting 2
... Duke University Medical Center researchers, African-Americans have a notably ... hepatitis C than non-Hispanic whites. ,The ... which is the journal for the members of the ... with hepatitis C (HCV) infections experience a reduced response ...
... A new study published in the Journal of Neurology, Neurosurgery ... during //two peak periods. Japanese researchers who conducted the study ... and 8am and 6pm and 8pm. ,The researchers examined ... was lowest during sleep. This may probably be due to ...
... Health Service Executive in Ireland is all set to offer ... overcrowding.// ,The Irish Examiner reports that hospitals may be ... the A&E crisis, where patients are made to wait for ... patients are not made to wait over 24 hours. Also ...
... University of Siena, researchers found that cartoons are twice as ... medical procedures, such as having a blood sample taken. ... Scatte Clinic divided 69 children, aged between 7 and 12, ... kids started watching TV cartoons at least two minutes before ...
... a little extra income can make a big difference in helping ... the upper end," said Meredith Minkler, an author of a report ... England Journal of Medicine. "We always knew there was a major ... that the middle class was at a substantial disadvantage to slightly ...
... west of Scotland; Inverclyde, is to be revamped.// ... and increase in the range of community-based services will ... ,An already existing ward at Inverclyde Royal Hospital ... Children's hospital services, therapy services currently provided by ...
Cached Medicine News:Health News:African-Americans Have A Reduced Response To Hepatitis C Treatment 2Health News:African-Americans Have A Reduced Response To Hepatitis C Treatment 3Health News:The higher the income the lower the disability rates! 2Health News:A new deal for childcare services given go-ahead 2
... is a primary component of an integrated ... sampling, and slide preparation all strictly ... LBP Processor produces high-quality sample slides featuring ... of cytology specimen types. It processes 40 ...
... offer a safe alternative to using positive ... applications such as PCR(a), pipetting radioactive materials ... are excellent for tissue culture, gel loading, ... prevent aerosol contaminants and liquids from reaching ...
... Packed conveniently in plastic-wrapped racks of ... to useno need to autoclave. Sterilized Diamond ... efficient sterilization and are delivered with a ... irradiation. Sterilized Diamond Tips are certified free ...
... been designed to optimize the accuracy and ... tip products is widely recognized by customers ... been extended over the years and now ... special tips including filter tips, certified pure ...
Medicine Products: